Skip to Main Content

During the pandemic, regulatory agencies deployed emergency measures left and right to speed care to patients.

Today, that’s leaving the health care industry, and especially younger digital startups, in a tricky spot. Companies have benefited from the reduced regulatory burden of the pandemic — but it’s unclear how long they’ll get to ride the gravy train. “What’s going to happen is the regulatory agencies are required to essentially go back to the way it was before,” said Amy Abernethy, former deputy principal commissioner and acting CIO at the FDA. “But we don’t unlearn.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment